Latest News

Research Update CHF 02723 MY3: Scientific and Clinical Assessment of Fecal Microbiota Transplant in Obese Dogs: SLIM Study

We screened (comprehensive physical examinations, bloodwork, and fecal analysis) 51 dogs for the SLIM study. Of these, 31 met the inclusion criteria and were enrolled. Of these enrolled dogs, 25 dogs completed the 24-week clinical trial. Unfortunately, 6 dogs were removed from the study early with the most common reason related to administration of antimicrobials needed for underlying health conditions including dog bite wounds, urinary tract infections, and surgical procedures. Based on recalculating our power analysis for sample size estimation, out current samples size (n=25) is sufficient to find a significant difference in weight loss between the treatment groups. Our last SLIM patient finished the clinical trial at the end of October 2022. Since this time, we have entered the analysis phase and sample processing for microbiome sequencing and metabolomics. Continue reading “Research Update CHF 02723 MY3: Scientific and Clinical Assessment of Fecal Microbiota Transplant in Obese Dogs: SLIM Study”

Research Update CHF 02758 FINAL: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms

Thank you for supporting our project titled “Optical coherence tomography for margin evaluation of skin and subcutaneous neoplasms”. This project is investigating an emerging diagnostic imaging tool, optical coherence tomography that uses light waves to generate real time high-resolution images of tissues for detection of residual cancer cells immediately following surgical removal. Our team involves collaboration between veterinary medicine and pathology at the Ohio State University. We have completed enrollment of the 80 cases. We completed the first phase of this project where we are looking at imaging skin tumors after surgical removal in dogs. Continue reading “Research Update CHF 02758 FINAL: Optical Coherence Tomography for Margin Evaluation of Canine Skin and Subcutaneous Neoplasms”

Research Update CHF 02624 Final: Embracing Polygenicity of Common Complex Disease in Dogs: Genome-wide Association of Cruciate Ligament Rupture

We have now completed recruitment and marker genotyping of Labrador Retriever dogs under this award. A final single nucleotide polymorphism (SNP) marker data set of 1,006 dogs has been assembled and filtered for data analysis, slightly exceeding what was promised under the award. We have now completed analysis of these data to estimate heritability of cruciate ligament rupture, determined the extent of the polygenicity of the disease, and developed a genetic testing method for accurately predicting risk of cruciate ligament rupture. Continue reading “Research Update CHF 02624 Final: Embracing Polygenicity of Common Complex Disease in Dogs: Genome-wide Association of Cruciate Ligament Rupture”

Research Update 02945-MOU MY2: Understanding the genetic basis of Addison’s disease in Portuguese Water Dogs

Over the 1.5 years of this study, we have focused primarily on sample collection and running an initial set of genetics experiments. We collected samples mostly through PWD-related channels working directly with our collaborators in the PWDF/PWDCA. Continue reading “Research Update 02945-MOU MY2: Understanding the genetic basis of Addison’s disease in Portuguese Water Dogs”

Research Update CHF 02783 MY3: Transcriptional Profiling of Canine Soft Tissue Sarcoma

Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 MY3: Transcriptional Profiling of Canine Soft Tissue Sarcoma”

Research Update CHF 02780 MY3: Bladder Carcinogen Exposures in Pet Dogs

Bladder cancer case recruitment has been steady through our alliance with Antech, which is attaching our study flyer to all BRAF urine tests that are positive for bladder cancer. We are now enrolling 2-3 dogs with bladder cancer per month. We also have a list of possible matched controls through our expanded outreach through Facebook. We have recorded questionnaire data encoded for all dog kits that have been returned to us. Continue reading “Research Update CHF 02780 MY3: Bladder Carcinogen Exposures in Pet Dogs”

Research Update CHF 02819 MY2: Identification of Bartonella henselae In Vivo Induced Antigens for Development of a Reliable Serodiagnostic Assay for Canine Bartonelloses

We are on track to accomplish all of our aims for this study. Due to COVID-19 pandemic and backorders of supplies, we had a short delay in starting the study. We have now received all the lab supplies. Screening of Bh SA2 expression genomic library by colony immunoblotting (Aim1) require additional time and research effort to identify potential diagnostic antigens for canine bartonelloses. Continue reading “Research Update CHF 02819 MY2: Identification of Bartonella henselae In Vivo Induced Antigens for Development of a Reliable Serodiagnostic Assay for Canine Bartonelloses”

Research Update CHF 02772 FINAL: Identifying Early Stage Ultra-rare Mutations as Predictive Biomarkers of Lymphoma in High-risk versus Low-risk Breeds Within the Dog Aging Project

The primary goal of this project is to test the hypothesis that breeds vary in risk of lymphoma due, at least in part, to breed-specific variation in rates of mutation in genes relevant to lymphoma. To test this hypotheses, we needed to gather blood samples from breeds at high risk and low risk of lymphoma, and from individuals of different ages within those breeds. We would then measure the frequency of rare mutations in several genes, and ask if this frequency is higher in breeds at relatively high risk of lymphoma. Continue reading “Research Update CHF 02772 FINAL: Identifying Early Stage Ultra-rare Mutations as Predictive Biomarkers of Lymphoma in High-risk versus Low-risk Breeds Within the Dog Aging Project”

Research Update CHF 02534 EY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We opened the trial on July 1, 2019. As of June 27, 2021, we have enrolled 18 dogs in the study and no dose limiting toxicities within the initial 21-day assessment period have been observed. Based on these results, we are continuing to enroll dogs at the highest dose of propranolol (1.3 mg/kg) being tested.

Propranolol and doxorubicin levels in the blood from all of the dogs enrolled to date have been analyzed. Continue reading “Research Update CHF 02534 EY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update CHF MY3 02686-A: Pattern of Thyroid Function Tests during Recovery from Acute Nonthyroidal Illness

Excerpt from MY3 of Dr. Bolton’s work.

As expected, 100% of dogs at that time of nonthyroidal illness diagnosed had a low total T4 and ~90% had a low total T3. These values returned to normal as the disease process resolved. Free T4 (low) and TSH (high) was normal in all but 8 cases. The TSH, in most cases, appeared to significantly increase at the 2- and/or 4-week rechecks, albeit still within the reference range. Interestingly, in three cases, the TSH increases above the reference range after normalization of all other thyroid hormones (total T4, free T4, total T3) prior to returning to normal.

Enunciating differences between the pattern of thyroid hormone recovery in dogs and humans with naturally occurring disease will be postponed until all cases are enrolled and analyzed.

Grant MY3 02686-A: Pattern of Thyroid Function Tests during Recovery from Acute Nonthyroidal Illness